FDA Issues Guidance on Form 483 Responses

March 23, 2026

FDA issued a draft guidance Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection to help human and animal drug and biologics manufacturers prepare adequate responses to the agency when the manufacturer receives a form 483 at the end of an inspection. The guidance provides recommendations on how to submit a clear and well-organized response to the agency that outlines the manufacturer’s plans to remediate the observations highlighted in the 483 and any other needed corrective and preventive actions.

FDA has found that inadequate or incomplete responses make it difficult for the agency to assess what the manufacturer has corrected and evaluate the manufacturer’s remediation activities. This can delay the agency’s ability to assess the manufacturer’s conformity with current good manufacturing practice requirements.

The agency encourages manufacturers to review the guidance document and provide comments by
May 08, 2026.

Request a Consultation

★★★★★

Working with Shelly on various new product launches over the last couple of years has been seamless. Quick and clear guidance is always what we get.

R.G. Client

I've been working with Shelly and her team at Garg law for a little while now and they are fantastic! Very responsive, professional and they certainly get things done. Extremely satisfied with their service and highly recommend.

Mike H. Client

Ms Garg helped my company navigate an FDA import issue. She achieved an excellent result, was very responsive and professional, and managed to keep the project within budget. She is a stellar attorney.

Dr. Sastry Client

I have been using Shelly Garg as FDA Counsel for 10+ years, since she was at another international law firm. While we continued to use the previous firm she was at (mainly due to the process required to change firms), we realized the quality of counsel was not the same. We have since been using Garg Law and the ease of use and trust in the knowledge was back instantly. Shelly has the skills to help me understand the regulations (by translating into layman's terms) and risks in a manner that is specific to my business. She is also extremely timely in her responses which is critical when we have a deadline mandated by the FDA. Many other attorneys cite the regulations which l've already read, but need further counsel. In my opinion, this demonstrates Shelly's in-depth knowledge of the regulations, how they pertain to the law, and how they are applicable IRL. Shelly's personable approach and pleasant manner in communication makes it very easy to have been work with her and have productive discussions on the best next steps. She truly has a passion iternational for all things FDA and I've learned so much from her.

Claire P. Client